Suzette Kox, MPharm, Secretary General of the International Generic and Biosimilar Medicines Association (IGBA), discusses challenges faced jointly by the US and EU biosimilars markets.
Interviews
Advertisement
Gillian Woollett, MA, DPhil, senior vice president, Avalere Health, discusses how confirming "sufficient likeness" in biosimilar development can and should replace the current "totality of the evidence” approach to biosimilar development.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
2
Hereditary Ovarian Cancer Genes Found Beyond Traditionally High-Risk Groups
3
Medicaid Expansion Associated With Lower Mortality in NSCLC
4
ACIP Delayed Hepatitis B Vaccine Schedule Vote Amid Safety Controversy
5
